Protalix BioTherapeutics, Inc. (PLX)

NYSEAMERICAN: PLX · Real-Time Price · USD

2.370

+0.050 (2.16%)

At close: Aug 4, 2026, 4:00 PM EDT

2.370

0.00 (0.00%)

After-hours: Aug 4, 2026, 4:01 PM EDT

Protalix BioTherapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	76.38	52.74	53.4	65.49	47.64	38.35
Revenue Growth	27.80%	-1.23%	-18.47%	37.48%	24.22%	-39.03%
Gross Profit	53.44	25.75	29.08	42.51	28.05	22
Operating Income	19.79	-5.5	3.92	10.46	-13.01	-20.46
Net Income	15.33	-6.6	2.93	8.31	-14.93	-27.58
Earnings Per Share	0.18	-0.08	0.04	0.09	-0.31	-0.62
EPS Growth	350.00%	-	-55.56%	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Pfizer (Ireland)	12.7	18.23	12.62	12.52	12.4	10.16
Fiocruz (Brazil)	-	11.06	11.03	10.4	9.45	6.4
Chiesi (Italy)	26.03	22.51	29.33	17.5	3.44	0.19
Revenue from License and R&D Services	27.16	0.94	0.42	25.08	22.35	21.6
Revenue (Total)	76.38	52.74	53.4	65.49	47.64	38.35

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	51.08	30.27	34.83	44.56	22.18	38.99
Total Debt	8.48	8.32	5.53	26.28	33.47	33.47
Net Cash (Debt)	42.6	21.95	29.3	18.28	-11.29	5.52
Net Cash Growth	44.38%	-25.09%	60.31%	-	-	-
Net Cash Per Share	0.52	0.28	0.36	0.22	-0.23	0.12

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	15.09	-11.99	8.67	-1.32	-25	-10.29
Capital Expenditures	-2.09	-1.64	-1.28	-1.15	-0.63	-1.46
Free Cash Flow	13	-13.63	7.39	-2.47	-25.63	-11.74
Free Cash Flow Growth	-	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	69.97%	48.82%	54.46%	64.91%	58.87%	57.37%
Operating Margin	25.91%	-10.43%	7.34%	15.97%	-27.32%	-53.36%
Pretax Margin	25.22%	-10.63%	7.78%	13.08%	-30.22%	-71.92%
Profit Margin	22.68%	-8.74%	10.07%	13.47%	-29.11%	-71.92%
FCF Margin	17.02%	-25.84%	13.84%	-3.77%	-53.80%	-30.62%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 4, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	12.27	-	47.00	19.78	-	-
Forward PE	-	10.29	3.94	13.17	60.89	111.67
P/FCF Ratio	14.38	-	19.29	-	-	-
PS Ratio	2.45	2.74	2.67	1.98	1.55	0.99